Company: Eisai Company, Ltd.
Drug Type: Small Molecule
Mechanism Type: Neuroprotection
Mechanism: E0302 (mecobalamin) is a coenzyme form of vitamin B(12), and acts as an important cofactor in the activities of B(12)-dependent methyltransferases. It is approve and marketed as a treatment for peripheral neuropathies in Japan. The mechanism of action in unknown, but some studies suggest that it is neuroprotective and leads to axonal regeneration.
U.S. Status for ALS: N/A
 Eisai Submits New Drug Application for Mecobalamin Ultra-High Dose Preparation as Treatment for Amyotrophic Lateral Sclerosis in Japan. JCN Newswire, 27 May 2015. Accessed 9 Mar 2016 from http://en.acnnewswire.com/press-release/english/22659/eisai-submits-new-drug-application-for-mecobalamin-ultra-high-dose-preparation-as-treatment-for-amyotrophic-lateral-sclerosis-in-japan.
 Eisai Withdraws new drug application for mecoblamain ultra-high dose prepation as treatment for amyotrophic lateral sclerosis. Eisai, 22 Mar 2016. Accessed 28 Mar 2016 from http://www.eisai.com/news/news201615.html
 A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS). ClinicalTrials.gov, 26 Feb 2016. Accessed 9 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT00445172
 Methylcobalamin facilitates collateral sprouting of donor axons and innervation of recipient muscle in end-to-side neurorrhaphy in rats. Liao, WC et al. PLoS One. 2013 Sep 30;8(9):e76302.
Last updated March 29th, 2016